May 7th, 2015
This week’s topics are a comparison of a retrievable inferior vena cava filter plus anticoagulation vs. anticogulation alone for recurrent PE, the cost effectiveness and population impact of statins for primary prevention in U.S. adults age 75 and older, and more.
April 28th, 2015
Despite a lack of supporting evidence many patients with acute venous thromboembolism (VTE) receive inferior vena cava filters to prevent pulmonary embolism (PE). Now a new study published in JAMA offers no evidence of benefit for the use of these devices in a high-risk population already receiving anticoagulant drugs. A group of French physicians randomized nearly 400 […]
June 17th, 2014
Jay Giri and Saurav Chatterjee discuss their meta-analysis of trials comparing thrombolytic therapy and conventional anticoagulation in patients at intermediate risk for pulmonary embolism.
June 17th, 2014
The role of thrombolytic therapy for the treatment of pulmonary embolism has been unclear, as it has been difficult to measure the precise balance between enhanced clot-dissolving efficacy and greater bleeding risk produced by thrombolysis when compared with conventional anticoagulation. A new meta-analysis published in JAMA analyzed data from 16 randomized trials including 2115 patients. Overall, […]
April 14th, 2014
This week’s topics include TOPCAT, fibrinolysis for those with intermediate-risk PE, and more.
March 24th, 2014
This week’s topics include non-leg venous thrombosis in critically ill adults, a comparison of factor Xa inhibitors and warfarin for preventing stroke and thromboembolism in atrial fibrillation, and more.
March 20th, 2014
Ian Neeland presents our latest case: A 42-year-old man with heart failure is found to have a large pulmonary embolus. Tell us how you’d manage his treatment.
March 6th, 2014
Inferior vena cava filters seem to offer protection against death from pulmonary embolism when compared with anticoagulant therapy, but they have no significant effect on all-cause mortality. In addition, the filters are associated with higher rates of recurrent venous thromboembolism, according to an article in the Journal of the American College of Cardiology. Researchers examined data […]
December 18th, 2013
A new study helps support a role for the new oral anticoagulant dabigatran (Pradaxa, Boehringer Ingelheim) in patients with venous thrombosis (VTE). The RE-COVER II trial, published online in Circulation, confirms the finding of the earlier and highly similar RE-COVER trial, published in the New England Journal of Medicine in 2009, that dabigatran is as safe and effective as warfarin for […]
September 25th, 2013
Christopher Kabrhel discusses his research group’s study of the factors associated with clinical deterioration and the need for hospital-based interventions after an acute pulmonary embolism.